​
​

Y-mAbs Therapeutics Ownership | Who Owns Y-mAbs Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Y-mAbs Therapeutics Ownership Summary

Y-mAbs Therapeutics is owned by 55.63% institutional investors, 12.21% insiders, and 32.17% retail investors. Paradigm biocapital advisors lp is the largest institutional shareholder, holding 8.84% of YMAB shares. HBM Healthcare Investments AG Ord is the top mutual fund, with 7.40% of its assets in Y-mAbs Therapeutics shares.

YMAB Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockY-mAbs Therapeutics55.63%12.21%32.17%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Paradigm biocapital advisors lp3.87M8.84%$46.76M
Blackrock2.94M6.71%$35.50M
Sofinnova investments2.19M5.01%$26.51M
Vanguard group1.96M4.47%$23.64M
Polar capital1.83M4.18%$22.12M
Cormorant asset management, lp1.45M3.31%$17.52M
D. e. shaw926.46K2.12%$11.19M
State street804.61K1.84%$9.72M
Geode capital management765.64K1.75%$9.25M
Pictet asset management sa659.67K1.51%$7.97M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Paradigm biocapital advisors lp3.87M1.79%$46.76M
Caligan partners lp582.08K1.64%$7.03M
Sofinnova investments2.19M1.38%$26.51M
Cormorant asset management, lp1.45M1.01%$17.52M
Soleus capital management647.98K0.69%$7.83M
Virtus etf advisers27.33K0.16%$330.17K
Polar capital1.83M0.13%$22.12M
Entrypoint capital6.15K0.11%$74.32K
Boothbay fund management369.36K0.11%$4.46M
Rice hall james & associates89.73K0.07%$1.08M

Top Buyers

HolderShares% AssetsChange
Paradigm biocapital advisors lp3.87M1.79%1.64M
Cormorant asset management, lp1.45M1.01%1.45M
Blackrock2.94M0.00%81.46K
Soleus capital management647.98K0.69%77.00K
Squarepoint ops126.39K0.00%74.45K

Top Sellers

HolderShares% AssetsChange
Point72 asset management358.94K0.01%-1.17M
Acadian asset management323.18K0.01%-279.14K
Goldman sachs group138.74K0.00%-226.80K
Nuveen asset management112.48K0.00%-155.25K
D. e. shaw926.46K0.01%-141.70K

New Positions

HolderShares% AssetsChangeValue
Cormorant asset management, lp1.45M1.01%1.45M$17.52M
Swiss national bank60.30K0.00%60.30K$728.42K
Ubs asset management americas58.30K0.00%58.30K$704.25K
Alps advisors34.22K0.00%34.22K$413.43K
Virtus etf advisers27.33K0.16%27.33K$330.17K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-8.00
Advisor group-30.00
Point72 (difc)-53.00
Signaturefd-64.00
Highmark wealth management-220.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202496-3.03%24,352,7925.85%552.00%5113.33%34-20.93%
Mar 31, 2024996.45%23,007,88413.95%522.46%45-4.26%4338.71%
Dec 31, 202393-5.10%20,191,0852.81%462.29%4720.51%31-16.22%
Sep 30, 2023981.03%19,640,023-0.74%442.19%39-26.42%3719.35%
Jun 30, 20239712.79%19,785,4954.10%452.39%5312.77%3129.17%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
HBM Healthcare Investments AG Ord3.30M7.40%-
Polar Capital Biotech S Inc1.50M3.37%-
Vanguard Total Stock Mkt Idx Inv1.04M2.32%-
iShares Russell 2000 ETF951.95K2.14%-2.14K
Vanguard Institutional Extnd Mkt Idx Tr477.94K1.07%113.00
Pictet Biotech390.64K0.88%390.64K
Pictet-Biotech P USD386.99K0.87%-2.13K
SPDR® S&P Biotech ETF386.81K0.87%4.29K
Fidelity Small Cap Index377.28K0.85%-10.08K
iShares Russell 2000 Growth ETF327.48K0.73%-

Recent Insider Transactions

DateNameRoleActivityValue
Sep 16, 2024Gad Thomas CHIEF BUSINESS OFFICERSell$389.10K
Sep 13, 2024Gad Thomas CHIEF BUSINESS OFFICERSell$875.55K
Aug 28, 2024Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICERSell$768.50K
Aug 26, 2024Wilms Joris SVP & CHIEF OPERATING OFFICERSell$73.45K
Jun 10, 2024Ber Gerard-Sell$8.66K

Insider Transactions Trends

DateBuySell
2024 Q3-4
2024 Q2-7
2024 Q1-3
2023 Q4145
2023 Q22-

YMAB Ownership FAQ

Who Owns Y-mAbs Therapeutics?

Y-mAbs Therapeutics shareholders are primarily institutional investors at 55.63%, followed by 12.21% insiders and 32.16% retail investors. The average institutional ownership in Y-mAbs Therapeutics's industry, Biotech Stocks , is 44.97%, which Y-mAbs Therapeutics exceeds.

Who owns the most shares of Y-mAbs Therapeutics?

Y-mAbs Therapeutics’s largest shareholders are Paradigm biocapital advisors lp (3.87M shares, 8.84%), Blackrock (2.94M shares, 6.71%), and Sofinnova investments (2.19M shares, 5.01%). Together, they hold 20.57% of Y-mAbs Therapeutics’s total shares outstanding.

Does Blackrock own Y-mAbs Therapeutics?

Yes, BlackRock owns 6.71% of Y-mAbs Therapeutics, totaling 2.94M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 35.5M$. In the last quarter, BlackRock increased its holdings by 81.46K shares, a 2.85% change.

Who is Y-mAbs Therapeutics’s biggest shareholder by percentage of total assets invested?

Paradigm biocapital advisors lp is Y-mAbs Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.79% of its assets in 3.87M Y-mAbs Therapeutics shares, valued at 46.76M$.

Who is the top mutual fund holder of Y-mAbs Therapeutics shares?

HBM Healthcare Investments AG Ord is the top mutual fund holder of Y-mAbs Therapeutics shares, with 7.40% of its total shares outstanding invested in 3.3M Y-mAbs Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools